Mesenchymal Stem Cell Therapy: Therapeutic Opportunities and Challenges for Diabetic Kidney Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Oct 16

PMID 39408867

Authors

Jia Cheng

Chun Zhang

Affiliations

Soon will be listed here.

Abstract

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD), which severely affects the quality of patients' lives. However, the current therapeutic approaches can only postpone its progression to ESRD. It is therefore imperative to develop a novel therapeutic strategy for renal injury in DKD, with the objective of restoring renal function and reversing the process of ESRD. In recent years, the potential of mesenchymal stem cell (MSC) therapy for DKD has garnered increasing attention within the scientific community. Preclinical research on MSC therapy has yielded promising results, and the safety of MSC treatment in vivo has been substantiated in clinical studies. An increasing body of evidence suggests that MSC therapy has significant potential for the treatment of DKD. This article reviews the existing research on MSCs and their derived exosomes in treating DKD and analyzes the underlying mechanism of MSC-based therapy for DKD. Additionally, we discuss the potential of combining MSC therapy with conventional pharmacological treatments, along with the constraints and prospects of MSC therapy for DKD. We hope this review can provide a precise and comprehensive understanding of MSCs for the treatment of DKD.

References

Nagaishi K, Mizue Y, Chikenji T, Otani M, Nakano M, Konari N . Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes. Sci Rep. 2016; 6:34842. PMC: 5056395. DOI: 10.1038/srep34842. View

Nguyen L, Hoang D, Nguyen K, Bui D, Nguyen H, Le H . Type 2 diabetes mellitus duration and obesity alter the efficacy of autologously transplanted bone marrow-derived mesenchymal stem/stromal cells. Stem Cells Transl Med. 2021; 10(9):1266-1278. PMC: 8380443. DOI: 10.1002/sctm.20-0506. View

Grange C, Tritta S, Tapparo M, Cedrino M, Tetta C, Camussi G . Stem cell-derived extracellular vesicles inhibit and revert fibrosis progression in a mouse model of diabetic nephropathy. Sci Rep. 2019; 9(1):4468. PMC: 6418239. DOI: 10.1038/s41598-019-41100-9. View

Lin R, Im G, Luo A, Zhu Y, Hong X, Neumeyer J . Mitochondrial transfer mediates endothelial cell engraftment through mitophagy. Nature. 2024; 629(8012):660-668. PMC: 11574736. DOI: 10.1038/s41586-024-07340-0. View

Zhang Y, Le X, Zheng S, Zhang K, He J, Liu M . MicroRNA-146a-5p-modified human umbilical cord mesenchymal stem cells enhance protection against diabetic nephropathy in rats through facilitating M2 macrophage polarization. Stem Cell Res Ther. 2022; 13(1):171. PMC: 9044847. DOI: 10.1186/s13287-022-02855-7. View

Wise A, Williams T, Rudd S, Wells C, Kerr P, Ricardo S . Human mesenchymal stem cells alter the gene profile of monocytes from patients with Type 2 diabetes and end-stage renal disease. Regen Med. 2015; 11(2):145-58. DOI: 10.2217/rme.15.74. View

Abumaree M, Al Jumah M, Kalionis B, Jawdat D, Al Khaldi A, AlTalabani A . Phenotypic and functional characterization of mesenchymal stem cells from chorionic villi of human term placenta. Stem Cell Rev Rep. 2012; 9(1):16-31. DOI: 10.1007/s12015-012-9385-4. View

Kim D, Staples M, Shinozuka K, Pantcheva P, Kang S, Borlongan C . Wharton's jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci. 2013; 14(6):11692-712. PMC: 3709752. DOI: 10.3390/ijms140611692. View

Li X, Li Y, Yu C, Bao H, Cheng S, Huang J . ROS-Responsive Janus Au/Mesoporous Silica Core/Shell Nanoparticles for Drug Delivery and Long-Term CT Imaging Tracking of MSCs in Pulmonary Fibrosis Treatment. ACS Nano. 2023; 17(7):6387-6399. DOI: 10.1021/acsnano.2c11112. View

10.

Xiang E, Han B, Zhang Q, Rao W, Wang Z, Chang C . Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis. Stem Cell Res Ther. 2020; 11(1):336. PMC: 7397631. DOI: 10.1186/s13287-020-01852-y. View

11.

Zhang H, Wang X, Hu B, Li P, Abuduaini Y, Zhao H . Human umbilical cord mesenchymal stem cells attenuate diabetic nephropathy through the IGF1R-CHK2-p53 signalling axis in male rats with type 2 diabetes mellitus. J Zhejiang Univ Sci B. 2024; 25(7):568-580. PMC: 11254681. DOI: 10.1631/jzus.B2300182. View

12.

Zhang C, Shang Y, Chen X, Midgley A, Wang Z, Zhu D . Supramolecular Nanofibers Containing Arginine-Glycine-Aspartate (RGD) Peptides Boost Therapeutic Efficacy of Extracellular Vesicles in Kidney Repair. ACS Nano. 2020; 14(9):12133-12147. DOI: 10.1021/acsnano.0c05681. View

13.

Ni Y, Chen Y, Jiang X, Pu T, Zhang L, Li S . Transplantation of Human Amniotic Mesenchymal Stem Cells Up-Regulates Angiogenic Factor Expression to Attenuate Diabetic Kidney Disease in Rats. Diabetes Metab Syndr Obes. 2023; 16:331-343. PMC: 9921454. DOI: 10.2147/DMSO.S371752. View

14.

Silva J, Su Y, Calfee C, Delucchi K, Weiss D, McAuley D . Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS. Eur Respir J. 2020; 58(1). PMC: 8318599. DOI: 10.1183/13993003.02978-2020. View

15.

Cui C, Zang N, Song J, Guo X, He Q, Hu H . Exosomes derived from mesenchymal stem cells attenuate diabetic kidney disease by inhibiting cell apoptosis and epithelial-to-mesenchymal transition via miR-424-5p. FASEB J. 2022; 36(10):e22517. DOI: 10.1096/fj.202200488R. View

16.

Hao Y, Miao J, Liu W, Cai K, Huang X, Peng L . Mesenchymal Stem Cell-Derived Exosomes Carry MicroRNA-125a to Protect Against Diabetic Nephropathy by Targeting Histone Deacetylase 1 and Downregulating Endothelin-1. Diabetes Metab Syndr Obes. 2021; 14:1405-1418. PMC: 8006976. DOI: 10.2147/DMSO.S286191. View

17.

Chen L, Xiang E, Li C, Han B, Zhang Q, Rao W . Umbilical Cord-Derived Mesenchymal Stem Cells Ameliorate Nephrocyte Injury and Proteinuria in a Diabetic Nephropathy Rat Model. J Diabetes Res. 2020; 2020:8035853. PMC: 7206880. DOI: 10.1155/2020/8035853. View

18.

Rao N, Wang X, Xie J, Li J, Zhai Y, Li X . Stem Cells from Human Exfoliated Deciduous Teeth Ameliorate Diabetic Nephropathy In Vivo and In Vitro by Inhibiting Advanced Glycation End Product-Activated Epithelial-Mesenchymal Transition. Stem Cells Int. 2019; 2019:2751475. PMC: 6913167. DOI: 10.1155/2019/2751475. View

19.

Yang C, Chen Y, Sung P, Chiang J, Chen C, Li Y . Repeated administration of adipose-derived mesenchymal stem cells added on beneficial effects of empagliflozin on protecting renal function in diabetic kidney disease rat. Biomed J. 2023; 47(2):100613. PMC: 10950825. DOI: 10.1016/j.bj.2023.100613. View

20.

Wang Y, Liu J, Wang H, Lv S, Liu Q, Li S . Mesenchymal Stem Cell-Derived Exosomes Ameliorate Diabetic Kidney Disease Through the NLRP3 Signaling Pathway. Stem Cells. 2023; 41(4):368-383. DOI: 10.1093/stmcls/sxad010. View